Yongchang Zhang, MD
Hunan Cancer Hospital
Emerging Leaders
not ranked
Current Leaders
#3247 pts
All-Time Leaders
#23934 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2018. 19 trials as lead/chair. How it works →
Trials led — by scientific impact
A Prospective, Multi-cohort Clinical Research of Efficacy and Safety of Bispecific Anti-PD-1 / PD-L1 Antibody IBI318 Combined with Lenvatinib in the Treatment of Advanced NSCLC
Phase 2RecruitingHunan Province Tumor Hospital
11
impact
A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure
Phase 2RecruitingHunan Province Tumor Hospital
5
impact
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
N/ARecruitingHunan Province Tumor Hospital
3
impact
Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.
Phase 2RecruitingHunan Province Tumor Hospital
2
impact
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
N/ARecruitingHunan Province Tumor Hospital
2
impact
SHR-1701 Combined With Fluzoparib as Maintenance Therapy for Advanced Lung Squamous Cell Carcinoma After Platium Based Chemo-immunotherapy
Phase 2UnknownHunan Province Tumor Hospital
2
impact
Anlotinib With or Without Immune Checkpoint Inhibitors in Standard Chemo-immunotherapy Failed Advanced Non-small Cell Lung Cancer
Phase 3RecruitingHunan Province Tumor Hospital
2
impact
A Prospective, Multi-cohort Study on Efficacy and Safety of IBI363 for Advanced Solid Tumors
Phase 2RecruitingHunan Province Tumor Hospital
2
impact
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ROS1-rearranged Non-squamous Non-small Cell Lung Cancer
N/AUnknownHunan Province Tumor Hospital
1
impact
Single Center, Single Arm Phase II Study on Efficacy Evaluation and Bio-marker Analysis of Sintilimab Combined With Docetaxel for Double Platinum-based Chemotherapy Failure Advanced Non-small Cell Lung Cancer
Phase 2CompletedHunan Province Tumor Hospital
1
impact
Evaluation of the Efficacy of Immunotherapy in Uncommon Pathological Types of Lung Cancer
N/ACompletedHunan Province Tumor Hospital
1
impact
A Real World Study to Evaluate the Efficacy and Safety of First Line Crizotinib in ALK Rearranged Advanced Non Squamous Non-small Cell Lung Cancer
N/AUnknownHunan Province Tumor Hospital
1
impact
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced Non-small Cell Lung Cancer
Phase 2RecruitingHunan Province Tumor Hospital
1
impact
Progression Survival Time According to Time-of-Day (ToD) of Administration of Immunochemotherapy for Advanced Non-small Cell Lung Cancer: A Phase III Randomized Control Trial
Phase 3CompletedHunan Province Tumor Hospital
0
impact
A Perspective Observation Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic NSCLC
Phase 2RecruitingHunan Province Tumor Hospital
0
impact
To Investigate the Efficacy and Resistance Mechanisms of Intrathecal Pemetrexed in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Harboring Oncogenic Mutations With Leptomeningeal Metastases
Phase 2RecruitingHunan Province Tumor Hospital
0
impact
A Phase II, Single-Arm Study Evaluating the 1st Line Efficacy and Safety of Sunvozertinib Plus Anlotinib in EGFR-Sensitive Mutations Combined With Co-Mutations Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (WUKONG-32)
Phase 2RecruitingHunan Province Tumor Hospital
0
impact
A Phase I/II Clinical Study on the Safety, Tolerability and Preliminary Efficacy of C019199 in Combination With Sintilimab in Patients With Advanced Solid Tumors
Phase 2ActiveFujian Haixi Pharmaceuticals Co., Ltd.
0
impact
Clinical Trials to Evaluate the Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in Patients With Non-small Cell Lung Cancer
N/ACompletedHunan Province Tumor Hospital
0
impact
Efficacy of Platinum-based Chemotherapy With or Without Immune Checkpoint Inhibitors in Patients With EGFR/ALK/ROS1 Sensitive Mutated NSCLC Who Progressed From Previous Tyrosine Kinase Inhibitors (TKI) Therapy
Phase 2RecruitingHunan Province Tumor Hospital
0
impact
Efficacy of Osimertinib in Patients With Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations
N/AUnknownHunan Province Tumor Hospital
0
impact
Chemotherapy Combined with Immune Checkpoint Inhibitors in Patients with ALK-rearranged Non-small Cell Lung Cancer (NSCLC) Who Have Progressed After First-line Alectinib: a Proof-of-concept, Phase 2 Trial
Phase 2CompletedHunan Province Tumor Hospital
0
impact
Molecular Characterization and Clinical Outcomes of ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma
Phase 2RecruitingHunan Province Tumor Hospital
0
impact
A Non-interventional Study and Its Clinical Relevance With Advanced Lung Squamous Cell Carcinoma
N/AUnknownHunan Province Tumor Hospital
0
impact
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors With or Without Chemotherapy
Phase 3RecruitingHunan Province Tumor Hospital
0
impact
Phase I Clinical Study on Dose-Escalation Tolerability and Pharmacokinetics of AL58805 in Patients With Advanced Tumors
Phase 1RecruitingAdvenchen Laboratories Nanjing Ltd.
0
impact
Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer ( Poseidon Study）
N/AUnknownHunan Province Tumor Hospital
0
impact
Chemotherapy or Chemotherapy Plus PD-1 Antibody in HER 2 Insertion or Amplification Advanced Non-small Cell Lung Cancer
N/ARecruitingHunan Province Tumor Hospital
0
impact
Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China
N/ARecruitingHunan Province Tumor Hospital
0
impact
Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC
N/ACompletedHunan Province Tumor Hospital
0
impact
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
N/ACompletedHunan Province Tumor Hospital
0
impact
Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy
N/ACompletedHunan Province Tumor Hospital
0
impact
Omprehensive First-in-Human Phase I/II Study of FHND-9041 in Patients With EGFR Mutated Advanced Non-Small Cell Lung Cancer
Phase 2CompletedYongchang Zhang
0
impact
Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer
Phase 2UnknownYongchang Zhang
0
impact
Consistency of Immunohistochemical Detecting Assays Using E1L3N and 22C3 Monoclonal Antibodies for Detection of PD-L1 Expression in NSCLC Patients: A Prospective CONFIDENCE Study
N/ACompletedHunan Province Tumor Hospital
0
impact